CN1308030C - Medicine combination containing valid part of Ruyi Jinhuangsan and its preparing method - Google Patents
Medicine combination containing valid part of Ruyi Jinhuangsan and its preparing method Download PDFInfo
- Publication number
- CN1308030C CN1308030C CNB031132901A CN03113290A CN1308030C CN 1308030 C CN1308030 C CN 1308030C CN B031132901 A CNB031132901 A CN B031132901A CN 03113290 A CN03113290 A CN 03113290A CN 1308030 C CN1308030 C CN 1308030C
- Authority
- CN
- China
- Prior art keywords
- parts
- wishes
- crude drug
- weight
- concentrated solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000003814 drug Substances 0.000 title claims abstract description 56
- 229940079593 drug Drugs 0.000 title claims description 46
- 238000000034 method Methods 0.000 title claims description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 62
- 239000007788 liquid Substances 0.000 claims abstract description 30
- 239000000203 mixture Substances 0.000 claims abstract description 28
- 238000002360 preparation method Methods 0.000 claims abstract description 22
- AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 claims abstract description 18
- 229960003639 laurocapram Drugs 0.000 claims abstract description 18
- 241000489492 Arisaema Species 0.000 claims abstract description 8
- 238000010992 reflux Methods 0.000 claims abstract description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 64
- 229940040145 liniment Drugs 0.000 claims description 60
- 239000000865 liniment Substances 0.000 claims description 60
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 30
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims description 20
- 238000002156 mixing Methods 0.000 claims description 14
- 229920003081 Povidone K 30 Polymers 0.000 claims description 13
- 238000012056 up-stream process Methods 0.000 claims description 13
- 239000002674 ointment Substances 0.000 claims description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims description 12
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 10
- 229940075507 glyceryl monostearate Drugs 0.000 claims description 10
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 claims description 10
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 claims description 10
- 229920001214 Polysorbate 60 Polymers 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 claims description 8
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical class [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 8
- 235000021355 Stearic acid Nutrition 0.000 claims description 8
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical group CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 8
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 8
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 claims description 8
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims description 8
- 239000008117 stearic acid Substances 0.000 claims description 8
- 210000000941 bile Anatomy 0.000 claims description 7
- 238000005325 percolation Methods 0.000 claims description 7
- 239000008517 radix Trichosanthis Substances 0.000 claims description 7
- 238000010438 heat treatment Methods 0.000 claims description 5
- 238000009413 insulation Methods 0.000 claims description 5
- 230000002829 reductive effect Effects 0.000 claims description 5
- 241000545442 Radix Species 0.000 claims description 4
- 239000012141 concentrate Substances 0.000 claims description 4
- 229940057995 liquid paraffin Drugs 0.000 claims description 4
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 claims description 4
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 claims description 4
- 229920000136 polysorbate Polymers 0.000 claims description 4
- 229950008882 polysorbate Drugs 0.000 claims description 4
- 229940113124 polysorbate 60 Drugs 0.000 claims description 4
- 229940099259 vaseline Drugs 0.000 claims description 4
- 238000009833 condensation Methods 0.000 claims description 3
- 230000005494 condensation Effects 0.000 claims description 3
- 235000019388 lanolin Nutrition 0.000 claims description 3
- -1 tincture Substances 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 2
- 229940098465 tincture Drugs 0.000 claims description 2
- 239000000890 drug combination Substances 0.000 claims 2
- FFRBMBIXVSCUFS-UHFFFAOYSA-N 2,4-dinitro-1-naphthol Chemical compound C1=CC=C2C(O)=C([N+]([O-])=O)C=C([N+]([O-])=O)C2=C1 FFRBMBIXVSCUFS-UHFFFAOYSA-N 0.000 abstract description 60
- 239000000843 powder Substances 0.000 abstract description 16
- 238000000605 extraction Methods 0.000 abstract description 10
- 239000011248 coating agent Substances 0.000 abstract description 3
- 238000000576 coating method Methods 0.000 abstract description 3
- 239000000463 material Substances 0.000 abstract description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 abstract 1
- 241000213006 Angelica dahurica Species 0.000 abstract 1
- 241000132012 Atractylodes Species 0.000 abstract 1
- 241000675108 Citrus tangerina Species 0.000 abstract 1
- 241000202807 Glycyrrhiza Species 0.000 abstract 1
- 241001673966 Magnolia officinalis Species 0.000 abstract 1
- 241000972673 Phellodendron amurense Species 0.000 abstract 1
- 244000299790 Rheum rhabarbarum Species 0.000 abstract 1
- 235000009411 Rheum rhabarbarum Nutrition 0.000 abstract 1
- 235000008326 Trichosanthes anguina Nutrition 0.000 abstract 1
- 244000078912 Trichosanthes cucumerina Species 0.000 abstract 1
- 235000003373 curcuma longa Nutrition 0.000 abstract 1
- 239000001215 curcuma longa l. root Substances 0.000 abstract 1
- LTINPJMVDKPJJI-UHFFFAOYSA-N iodinated glycerol Chemical compound CC(I)C1OCC(CO)O1 LTINPJMVDKPJJI-UHFFFAOYSA-N 0.000 abstract 1
- 230000037384 skin absorption Effects 0.000 abstract 1
- 231100000274 skin absorption Toxicity 0.000 abstract 1
- 238000012360 testing method Methods 0.000 description 28
- 239000000546 pharmaceutical excipient Substances 0.000 description 22
- 239000000243 solution Substances 0.000 description 19
- 241000700159 Rattus Species 0.000 description 18
- 230000002401 inhibitory effect Effects 0.000 description 16
- 241000699670 Mus sp. Species 0.000 description 15
- 230000000694 effects Effects 0.000 description 15
- 230000003110 anti-inflammatory effect Effects 0.000 description 14
- 230000001629 suppression Effects 0.000 description 14
- 230000037396 body weight Effects 0.000 description 12
- 208000025865 Ulcer Diseases 0.000 description 11
- 210000004369 blood Anatomy 0.000 description 11
- 239000008280 blood Substances 0.000 description 11
- 231100000397 ulcer Toxicity 0.000 description 11
- 239000000341 volatile oil Substances 0.000 description 11
- 210000003491 skin Anatomy 0.000 description 10
- 230000008961 swelling Effects 0.000 description 10
- 241000222122 Candida albicans Species 0.000 description 9
- 208000003251 Pruritus Diseases 0.000 description 9
- 229940095731 candida albicans Drugs 0.000 description 9
- 238000003756 stirring Methods 0.000 description 9
- 206010030113 Oedema Diseases 0.000 description 8
- 241000191967 Staphylococcus aureus Species 0.000 description 8
- 238000010521 absorption reaction Methods 0.000 description 8
- 230000000844 anti-bacterial effect Effects 0.000 description 8
- 239000004615 ingredient Substances 0.000 description 8
- 102000002322 Egg Proteins Human genes 0.000 description 7
- 108010000912 Egg Proteins Proteins 0.000 description 7
- 241000287828 Gallus gallus Species 0.000 description 7
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 7
- 230000003115 biocidal effect Effects 0.000 description 7
- 239000000499 gel Substances 0.000 description 7
- 238000005469 granulation Methods 0.000 description 7
- 230000003179 granulation Effects 0.000 description 7
- 239000001963 growth medium Substances 0.000 description 7
- 210000004681 ovum Anatomy 0.000 description 7
- 206010040872 skin infection Diseases 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 201000004624 Dermatitis Diseases 0.000 description 6
- 206010061926 Purulence Diseases 0.000 description 6
- LQGUBLBATBMXHT-UHFFFAOYSA-N chrysophanol Chemical compound C1=CC=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O LQGUBLBATBMXHT-UHFFFAOYSA-N 0.000 description 6
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 208000027418 Wounds and injury Diseases 0.000 description 5
- 230000001580 bacterial effect Effects 0.000 description 5
- 230000035617 depilation Effects 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 206010020718 hyperplasia Diseases 0.000 description 5
- VVOAZFWZEDHOOU-UHFFFAOYSA-N magnolol Chemical compound OC1=CC=C(CC=C)C=C1C1=CC(CC=C)=CC=C1O VVOAZFWZEDHOOU-UHFFFAOYSA-N 0.000 description 5
- 231100000915 pathological change Toxicity 0.000 description 5
- 230000036285 pathological change Effects 0.000 description 5
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 4
- 235000009161 Espostoa lanata Nutrition 0.000 description 4
- 240000001624 Espostoa lanata Species 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 229920002125 Sokalan® Polymers 0.000 description 4
- 241000194017 Streptococcus Species 0.000 description 4
- 241000193990 Streptococcus sp. 'group B' Species 0.000 description 4
- 230000000202 analgesic effect Effects 0.000 description 4
- 230000000840 anti-viral effect Effects 0.000 description 4
- 229960001631 carbomer Drugs 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000002481 ethanol extraction Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- 238000006748 scratching Methods 0.000 description 4
- 230000002393 scratching effect Effects 0.000 description 4
- 238000007920 subcutaneous administration Methods 0.000 description 4
- LOTKRQAVGJMPNV-UHFFFAOYSA-N 1-fluoro-2,4-dinitrobenzene Chemical compound [O-][N+](=O)C1=CC=C(F)C([N+]([O-])=O)=C1 LOTKRQAVGJMPNV-UHFFFAOYSA-N 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 241000700199 Cavia porcellus Species 0.000 description 3
- 229920000742 Cotton Polymers 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 3
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical group C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 3
- 230000003187 abdominal effect Effects 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 230000036592 analgesia Effects 0.000 description 3
- NZPQWZZXRKZCDU-UHFFFAOYSA-N chrysophanol Natural products Cc1cc(O)c2C(=O)c3c(O)cccc3Oc2c1 NZPQWZZXRKZCDU-UHFFFAOYSA-N 0.000 description 3
- 229940109262 curcumin Drugs 0.000 description 3
- 235000012754 curcumin Nutrition 0.000 description 3
- 239000004148 curcumin Substances 0.000 description 3
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000007803 itching Effects 0.000 description 3
- 230000017074 necrotic cell death Effects 0.000 description 3
- 230000036407 pain Effects 0.000 description 3
- 206010033675 panniculitis Diseases 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 238000004321 preservation Methods 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- CMDGQTVYVAKDNA-UHFFFAOYSA-N propane-1,2,3-triol;hydrate Chemical compound O.OCC(O)CO CMDGQTVYVAKDNA-UHFFFAOYSA-N 0.000 description 3
- 210000004304 subcutaneous tissue Anatomy 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000721047 Danaus plexippus Species 0.000 description 2
- 201000000297 Erysipelas Diseases 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 238000012449 Kunming mouse Methods 0.000 description 2
- 208000000114 Pain Threshold Diseases 0.000 description 2
- 239000004141 Sodium laurylsulphate Substances 0.000 description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000001139 anti-pruritic effect Effects 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 239000003908 antipruritic agent Substances 0.000 description 2
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N benzo-alpha-pyrone Natural products C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 235000001671 coumarin Nutrition 0.000 description 2
- 150000004775 coumarins Chemical class 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 229960001660 histamine phosphate Drugs 0.000 description 2
- ZHIBQGJKHVBLJJ-UHFFFAOYSA-N histamine phosphate Chemical compound OP(O)(O)=O.OP(O)(O)=O.NCCC1=CNC=N1 ZHIBQGJKHVBLJJ-UHFFFAOYSA-N 0.000 description 2
- OLOOJGVNMBJLLR-UHFFFAOYSA-N imperatorin Chemical compound C1=CC(=O)OC2=C1C=C1C=COC1=C2OCC=C(C)C OLOOJGVNMBJLLR-UHFFFAOYSA-N 0.000 description 2
- XKVWLLRDBHAWBL-UHFFFAOYSA-N imperatorin Natural products CC(=CCOc1c2OCCc2cc3C=CC(=O)Oc13)C XKVWLLRDBHAWBL-UHFFFAOYSA-N 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 230000037040 pain threshold Effects 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 229930182490 saponin Natural products 0.000 description 2
- 150000007949 saponins Chemical class 0.000 description 2
- 235000017709 saponins Nutrition 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- 239000001100 (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one Substances 0.000 description 1
- 240000006409 Acacia auriculiformis Species 0.000 description 1
- VKJGBAJNNALVAV-UHFFFAOYSA-M Berberine chloride (TN) Chemical compound [Cl-].C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 VKJGBAJNNALVAV-UHFFFAOYSA-M 0.000 description 1
- 229920000818 Catalin Polymers 0.000 description 1
- VWDXGKUTGQJJHJ-UHFFFAOYSA-N Catenarin Natural products C1=C(O)C=C2C(=O)C3=C(O)C(C)=CC(O)=C3C(=O)C2=C1O VWDXGKUTGQJJHJ-UHFFFAOYSA-N 0.000 description 1
- 206010014025 Ear swelling Diseases 0.000 description 1
- 239000010282 Emodin Substances 0.000 description 1
- RBLJKYCRSCQLRP-UHFFFAOYSA-N Emodin-dianthron Natural products O=C1C2=CC(C)=CC(O)=C2C(=O)C2=C1CC(=O)C=C2O RBLJKYCRSCQLRP-UHFFFAOYSA-N 0.000 description 1
- YOOXNSPYGCZLAX-UHFFFAOYSA-N Helminthosporin Natural products C1=CC(O)=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O YOOXNSPYGCZLAX-UHFFFAOYSA-N 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- QUQPHWDTPGMPEX-UHFFFAOYSA-N Hesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(COC4C(C(O)C(O)C(C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-UHFFFAOYSA-N 0.000 description 1
- BYTORXDZJWWIKR-UHFFFAOYSA-N Hinokiol Natural products CC(C)c1cc2CCC3C(C)(CO)C(O)CCC3(C)c2cc1O BYTORXDZJWWIKR-UHFFFAOYSA-N 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- 206010048865 Hypoacusis Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- RCEAADKTGXTDOA-UHFFFAOYSA-N OS(O)(=O)=O.CCCCCCCCCCCC[Na] Chemical compound OS(O)(=O)=O.CCCCCCCCCCCC[Na] RCEAADKTGXTDOA-UHFFFAOYSA-N 0.000 description 1
- 244000137852 Petrea volubilis Species 0.000 description 1
- OKPNYGAWTYOBFZ-UHFFFAOYSA-N Pirenoxine Chemical compound C12=NC3=CC=CC=C3OC2=CC(=O)C2=C1C(=O)C=C(C(=O)O)N2 OKPNYGAWTYOBFZ-UHFFFAOYSA-N 0.000 description 1
- 229920001219 Polysorbate 40 Polymers 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- NTGIIKCGBNGQAR-UHFFFAOYSA-N Rheoemodin Natural products C1=C(O)C=C2C(=O)C3=CC(O)=CC(O)=C3C(=O)C2=C1O NTGIIKCGBNGQAR-UHFFFAOYSA-N 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 206010053262 Skin swelling Diseases 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 108010021119 Trichosanthin Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- PYKYMHQGRFAEBM-UHFFFAOYSA-N anthraquinone Natural products CCC(=O)c1c(O)c2C(=O)C3C(C=CC=C3O)C(=O)c2cc1CC(=O)OC PYKYMHQGRFAEBM-UHFFFAOYSA-N 0.000 description 1
- 150000004056 anthraquinones Chemical class 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- QUQPHWDTPGMPEX-UTWYECKDSA-N aurantiamarin Natural products COc1ccc(cc1O)[C@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1 QUQPHWDTPGMPEX-UTWYECKDSA-N 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- XFQYJNINHLZMIU-UHFFFAOYSA-N cataline Natural products CN1CC(O)C2=CC(OC)=C(OC)C3=C2C1CC1=C3C=C(OC)C(OC)=C1 XFQYJNINHLZMIU-UHFFFAOYSA-N 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- APSNPMVGBGZYAJ-GLOOOPAXSA-N clematine Natural products COc1cc(ccc1O)[C@@H]2CC(=O)c3c(O)cc(O[C@@H]4O[C@H](CO[C@H]5O[C@@H](C)[C@H](O)[C@@H](O)[C@H]5O)[C@@H](O)[C@H](O)[C@H]4O)cc3O2 APSNPMVGBGZYAJ-GLOOOPAXSA-N 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 208000027744 congestion Diseases 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 238000007872 degassing Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- RHMXXJGYXNZAPX-UHFFFAOYSA-N emodin Chemical compound C1=C(O)C=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O RHMXXJGYXNZAPX-UHFFFAOYSA-N 0.000 description 1
- VASFLQKDXBAWEL-UHFFFAOYSA-N emodin Natural products OC1=C(OC2=C(C=CC(=C2C1=O)O)O)C1=CC=C(C=C1)O VASFLQKDXBAWEL-UHFFFAOYSA-N 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002213 flavones Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 210000003194 forelimb Anatomy 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 210000004013 groin Anatomy 0.000 description 1
- QUQPHWDTPGMPEX-QJBIFVCTSA-N hesperidin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]4[C@@H]([C@H](O)[C@@H](O)[C@H](C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-QJBIFVCTSA-N 0.000 description 1
- VUYDGVRIQRPHFX-UHFFFAOYSA-N hesperidin Natural products COc1cc(ccc1O)C2CC(=O)c3c(O)cc(OC4OC(COC5OC(O)C(O)C(O)C5O)C(O)C(O)C4O)cc3O2 VUYDGVRIQRPHFX-UHFFFAOYSA-N 0.000 description 1
- 229940025878 hesperidin Drugs 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- FVYXIJYOAGAUQK-UHFFFAOYSA-N honokiol Chemical compound C1=C(CC=C)C(O)=CC=C1C1=CC(CC=C)=CC=C1O FVYXIJYOAGAUQK-UHFFFAOYSA-N 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 229940087305 limonene Drugs 0.000 description 1
- 235000001510 limonene Nutrition 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 208000010553 multiple abscesses Diseases 0.000 description 1
- ARGKVCXINMKCAZ-UHFFFAOYSA-N neohesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(CO)O3)OC3C(C(O)C(O)C(C)O3)O)=CC(O)=C2C(=O)C1 ARGKVCXINMKCAZ-UHFFFAOYSA-N 0.000 description 1
- 210000004493 neutrocyte Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- PKUBGLYEOAJPEG-UHFFFAOYSA-N physcion Natural products C1=C(C)C=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O PKUBGLYEOAJPEG-UHFFFAOYSA-N 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000000249 polyoxyethylene sorbitan monopalmitate Substances 0.000 description 1
- 235000010483 polyoxyethylene sorbitan monopalmitate Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229940101027 polysorbate 40 Drugs 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 230000037075 skin appearance Effects 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to medicinal composition containing effective parts of agreeable golden yellow powder of a traditional Chinese medicine and a preparation method thereof. Turmeric root tuber, dahurian angelica, dried tangerine peel, officinal magnolia bark and atractylodes rhizome are percolated with ethanol, rhubarb, phellodendron bark, glycyrrhiza, raw arisaema and snakegourd root are in reflux extraction with ethanol, and concentrated alcohol liquid is added with selected auxiliary materials comprising quantitative laurocapram; compared with the traditional agreeable golden yellow powder, the external preparation of the present invention has the advantages of easy use, rapid action, stable effective components, stable physicochemical properties of the preparation, good coating performance, high effective component content and high dermal absorption rate.
Description
Technical field
The present invention relates to pharmaceutical composition that contains Chinese medicine compound ruyi jinhuang powder, ruyi jinhuang san effective site and preparation method thereof, specifically extract the effective site of ruyi jinhuang powder, ruyi jinhuang san, be mixed and made into all kinds of external preparation with suitable adjuvant.
Background technology
Ruyi jinhuang powder, ruyi jinhuang san is to go through edition kind that Pharmacopoeia of People's Republic of China recorded, and has the effect of reducing swelling and alleviating pain, is used for skin infection and swells and ache, and erysipelas stream is general, injury from falling down.Radix Et Rhizoma Rhei in the side, the detoxifcation of relieving inflammation or internal heat, promoting blood circulation and detumescence, the Cortex Phellodendri heat clearing and damp drying, removing toxic substances and promoting subsidence of swelling is monarch drug altogether; Be aided with Rhizoma Curcumae Longae, Radix Angelicae Dahuricae removing blood stasis with potent drugs promoting of the circulation of QI and removing the obstruction in the collaterals is dredged and is stopped up stagnant QI and blood, is accessory drugs; Arisaema Cum Bile, Rhizoma Atractylodis, Cortex Magnoliae Officinalis, Pericarpium Citri Reticulatae phlegm-eliminiating and qi-regulating, mass dissipating and swelling eliminating has the effect of crowding around of hoop collection; The pollen clearing heat for detumescence is adjuvant drug altogether; Radix Glycyrrhizae tool heat-clearing and toxic substances removing, and can coordinating the actions of various ingredients in a prescription be messenger drug.All medicines share, have relieve inflammation or internal heat, dissipating blood stasis, detumescence, pain relieving, the effect of crowding around.Yet powder uses very inconvenience, both affects the treatment, and also influences the scope of application and popularization.
Summary of the invention
The technical problem to be solved in the present invention is by analyzing the physicochemical property of effective site in the ruyi jinhuang powder, ruyi jinhuang san, design high efficiency extraction technology, and the effective site of ruyi jinhuang powder, ruyi jinhuang san combined with suitable adjuvant, prepare all kinds of external preparation with antibiotic, antiinflammatory, pain palliation efficacy, be specially and both can be used for skin infection and swell and ache, the erysipelas multiple abscess, injury from falling down can be used for decubital ulcer and phlebitic novel pharmaceutical formulation again.
External preparation of the present invention is compared with traditional ruyi jinhuang powder, ruyi jinhuang san, and not only easy to use, effect rapidly, effective component content is high, and the transdermal absorption factor height, active ingredient is stable, the preparation physicochemical character is stable, as external preparation, also needs coating performance good.
For addressing the above problem, the invention provides following technical solution.
A kind of externally-applied medicinal composition, available following method preparation:
Get 2～3 parts in Rhizoma Curcumae Longae, 2～3 parts of the Radixs Angelicae Dahuricae, 0.5～2 part of Pericarpium Citri Reticulatae, 0.5～2 part of Cortex Magnoliae Officinalis, 0.5～2 part of Rhizoma Atractylodis, with 85～95% ethanol percolations, the concentrating under reduced pressure percolate gets concentrated solution A to 5g crude drug/ml;
Get 2～3 parts of Radix Et Rhizoma Rhei, 2～3 parts of Cortex Phellodendris, 1 part in Radix Glycyrrhizae, 1 part of Arisaema Cum Bile, 4～6 parts of Radix Trichosanthis, with 55～65% alcohol reflux: concentrate ethanol liquid to 2g or 4g crude drug/ml, concentrated solution B;
Get 1 part of A concentrated solution by volume: B concentrated solution 0.5-1 part, mix with pharmaceutically acceptable carrier.
Described pharmaceutical composition is characterized in that:
Get 2.5 parts in Rhizoma Curcumae Longae, 2.5 parts of the Radixs Angelicae Dahuricae, 1 part of Pericarpium Citri Reticulatae, 1 part of Cortex Magnoliae Officinalis, 1 part of Rhizoma Atractylodis, use 90% ethanol percolation, the concentrating under reduced pressure percolate gets concentrated solution A to 5g crude drug/ml;
Get 2.5 parts of Radix Et Rhizoma Rhei, 2.5 parts of Cortex Phellodendris, 1 part in Radix Glycyrrhizae, 1 part of Arisaema Cum Bile, 5 parts of Radix Trichosanthis, with 8～10 times of amount 60% alcohol reflux; Concentrate ethanol liquid to 2g or 4g crude drug/ml, get concentrated solution B.
Aforementioned pharmaceutical composition can be made into liniment, ointment, tincture, unguentum or gel, rubber-emplastrum, emplastrum or cataplasma.
Liniment mainly is made up of with an amount of 50-75% ethanol 1 part of the B concentrated solution of 1 part of the A concentrated solution of 5g crude drug/ml by volume, 2g crude drug/ml.Also comprise 3～4.5% laurocaprams and/or dimethyl sulfoxide, 3～4.5% Tween-80s, polysorbate 60 and/or polysorbate 40,5～7% propylene glycol and/or PEG400 by volume in the liniment, and an amount of glycerol.
The preparation method of liniment comprises the steps:
Get 1 part of A concentrated solution and 3～4.5% laurocaprams and/or dimethyl sulfoxide mixing; Get 1 part of B concentrated solution and 3～4.5% polyoxyethylene sorbitan monoleate, polysorbate 60 and/or polysorbate 40,5～7% propylene glycol and/or PEG400 and an amount of glycerol mixing; Above-mentioned two liquid are mixed, add an amount of ethanol.
Ointment is mainly by 50 parts of the B concentrated solutions of 100 parts of the A concentrated solutions of 5g crude drug/ml, 4g crude drug/ml, with 30 POVIDONE K 30 BP/USP 30, beta-schardinger dextrin-and/or 1520～40 parts of 30 POVIDONE K 30 BP/USPs, 10～30 parts of sodium lauryl sulphates, glycerol and/or 150～300 parts of PEG400, lanoline, vaseline and/or 18～38 parts of liquid paraffin, 20～40 parts of compositions of stearic acid by weight.Can comprise also in the ointment that 18～38 parts of hexadecanol, 6～18 parts, 1: 1 glycerol of glyceryl monostearate and aqueous mixtures are an amount of by weight, and the laurocapram of gross weight 2～4%.
Described ointment is basically by 50 parts of the B concentrated solutions of 100 parts of the A concentrated solutions of 5g crude drug/ml, 4g crude drug/ml, with 3025～35 parts of 30 POVIDONE K 30 BP/USPs, 15～25 parts of sodium lauryl sulphates, 190～240 parts of glycerol, 22～30 parts of lanolines, 25～35 parts of stearic acid, 20～30 parts of hexadecanol, 8～14 parts, 1: 1 glycerol of glyceryl monostearate and aqueous mixtures are an amount of by weight, and the laurocapram of gross weight 2.5～3.5% is formed.
The preparation method of ointment comprises the steps:
100 parts of A concentrated solutions getting 5g crude drug/ml mix for 25～35 parts with 30 POVIDONE K 30 BP/USP 30, beta-schardinger dextrin-and/or 30 POVIDONE K 30 BP/USP makes dissolving, 1; 50 parts of B concentrated solutions getting 4g crude drug/ml and 15～25 parts of sodium lauryl sulphates and glycerol and/or PEG400 mix for 190～240 parts, heating in water bath, 2; Getting 20～30 parts of lanoline, vaseline and/or 22～30 parts of liquid paraffin, 25～35 parts of stearic acid, hexadecanol mixes for 8～14 parts with glyceryl monostearate, after the heat fused, add laurocapram, mixing by gross weight 2.5～3.5%, heat in the water-bath, get 3; Mix with 23, insulation 75 degree are cooled to 42～45 degree, as 4; 1 insulation to 35～40 degree, is added in 4, and 1: 1 the glycerol and the aqueous mixtures that replenish 35～40 degree are an amount of, natural condensation.
It is preferred that orthogonal test has been carried out in the extraction of Radix Et Rhizoma Rhei, Cortex Phellodendri, Arisaema Cum Bile, Radix Trichosanthis and Radix Glycyrrhizae, adopts ethanol extraction, and to the principal element concentration of alcohol of ethanol extraction, ethanol consumption and extraction time are carried out L by three factors, three levels
9(3)
4Orthogonal test.Result of the test shows that the principal element that influences extraction ratio is concentration of alcohol and ethanol consumption, to adopt 55～65% ethanol extractions better, is good with 60% ethanol extraction especially; Add 8～12 times of amounts and extract 2～3 times, got final product in each 1～2 hour, extract 2 times with 10 times of alcohol amounts, each 1.5 hours is good.
Radix Et Rhizoma Rhei mainly contains anthraquinone component, has antibiotic and antiinflammatory action.Cortex Phellodendri mainly contains the alkaloids composition, has effects such as antibiotic, antiviral, antifungal and antiinflammatory.Radix Glycyrrhizae mainly contains saponin component, has effects such as anti inflammatory immunity, antibiotic, antiviral.Rhizoma Arisaematis mainly contains compositions such as saponins, has analgesic activity.Radix Trichosanthis mainly contains trichosanthin and polysaccharide composition, has antibacterial action.Above Chinese medicine of the five flavours adopts alcohol reflux, serves as to investigate index with active ingredient emodin in the monarch drug Radix Et Rhizoma Rhei and the effective ingredient berberine hydrochloride in the Cortex Phellodendri, and its extraction ratio reaches 92.7% and 84.1% respectively, can more fully propose effective ingredient.
It is preferred that the extraction process of Rhizoma Curcumae Longae, the Radix Angelicae Dahuricae, Pericarpium Citri Reticulatae, Cortex Magnoliae Officinalis, Rhizoma Atractylodis has been carried out contrast, result of the test shows: 80～95% ethanol percolations are adopted in the extraction of Rhizoma Curcumae Longae, the Radix Angelicae Dahuricae, Pericarpium Citri Reticulatae, Cortex Magnoliae Officinalis, Rhizoma Atractylodis, preferred 90% ethanol percolation, the extraction efficiency height of effective ingredient curcumin, imperatorin and volatile oil not only, and dried cream yield is low, it is the effective component content height, especially it is higher to have Rhizoma Curcumae Longae volatile oil and curcumin content antibiotic and antiinflammatory and antiviral activity, and reduced and had thermo-labile, light fugitive photograph, the decomposition of the curcumin of water insoluble characteristic; All there is the Rhzoma Atractylodis Lanceae volatile oil of significant killing action to extract more complete to virus, mycoplasma, group B streptococcus, staphylococcus aureus, flavacin etc.; To Diplococcus pneumoniae, alpha streptococcus, catalin diplococcus, staphylococcus aureus all has the limonene in the very strong inhibiting Pericarpium Citri Reticulatae volatile oil, and the flavones ingredient Hesperidin with antiinflammatory, antiviral activity also extracts more complete; Also comprise compositions such as the volatile oil of Cortex Magnoliae Officinalis and lignanoid, lignanoid is mainly magnolol and honokiol, and magnolol has significant antibacterial action; Radix Angelicae Dahuricae volatile oil and Coumarins composition also extract more complete, and its volatile oil has antiinflammatory action, and Coumarins composition imperatorin has antibiotic, antiinflammatory action.Above Chinese medicine of the five flavours all contains volatile oil, and volatile oil not only is main effective ingredient, also has a transdermal facilitation.Antibiotic, antiinflammatory, disease-resistant composition are liposoluble constituent, therefore adopt ethanol percolate extraction, and cryoconcentration becomes thick paste, propose and keep volatile oil and be subject to pyrolysated active component.
Orthogonal test is adopted in research in the liniment preparation process, by the transdermal test in vitro absorption test, percutaneous absorption rate constant with the effective ingredient chrysophanol in the Radix Et Rhizoma Rhei is an index, and the amount of hanging the tall and erect ketone of nitrogen, polyoxyethylene sorbitan monoleate and propylene glycol the major influence factors pharmaceutical adjunct moon that influences Transdermal absorption is pressed three factors, three horizontal L
9(3)
4Orthogonal test.Result of the test shows that the principal element that influences Transdermal absorption is the amount of laurocapram, can add in the preparation and count 3～4.5% laurocaprams by volume, 3～4.5% Tween-80s, 5～7% propylene glycol; Add 4% laurocapram in the preparation, 4% polyoxyethylene sorbitan monoleate, 6% propylene glycol are good.
The cream preparation technical study at first adopts orthogonal test, has carried out preferred to the emulsifiable paste matrix prescription.With emulsion droplet size, appearance character and coating performance after the emulsifiable paste molding serves as to investigate index, and to principal element: the amount of the amount of the amount of lanoline, stearic amount, sodium lauryl sulphate, the amount of glyceryl monostearate, hexadecanol, the amount of glycerol and 30 POVIDONE K 30 BP/USP 30 carry out L by 7 factors, two levels
8(2)
7Orthogonal test.On the basis of above-mentioned preferred emulsifiable paste prescription, consumption (0%-4%) to the Percutaneous absorption enhancer laurocapram has carried out preferably, by the transdermal test in vitro absorption test, absorption rate constant with the effective ingredient chrysophanol in the Radix Et Rhizoma Rhei is an index, result of the test shows: it is better to add 2～4% laurocapram effect, the best results of 3% laurocapram.
Golden yellow liniment as one wishes and ointment pharmacodynamics test.
The comply with one's wishes golden yellow liniment and the golden yellow emulsifiable paste of complying with one's wishes shows through large and small Mus and Cavia porcellus result of the test: 1, significant analgesia role is arranged, can improve the pain threshold that causes of mice, that reduces that acetic acid causes turns round the body number of times; 2, have certain antiinflammatory action, suppress dimethylbenzene and cause the ear swelling of mice, Ovum Gallus domesticus album is caused that foot swelling of rat and the granulation hyperplasia that cotton balls causes also have the obvious suppression effect, there were significant differences with excipient group ratio.3, repercussive eliminating stagnation function well.The golden yellow liniment of complying with one's wishes can resist the blood stasis phenomenon that freely falling body produces rat with the golden yellow emulsifiable paste of complying with one's wishes, and the blood stasis tissue is taken an evident turn for the better.4, external bacteriostasis shows, the comply with one's wishes golden yellow liniment and the golden yellow emulsifiable paste of complying with one's wishes have to a certain degree inhibitory action to 6 kinds of antibacterials, and the golden yellow liniment of complying with one's wishes is to the strongest MIC of Candida albicans effect
50Be 3.12mg/ml, and the golden yellow emulsifiable paste of complying with one's wishes is to the strongest MIC of Candida albicans effect
50Be 6.25mg/ml, the local skin infection experiment shows that the comply with one's wishes golden yellow liniment and the golden yellow emulsifiable paste of complying with one's wishes obviously resist the skin infection that staphylococcus aureus causes, and make the very fast disappearance of purulence thing, ooze out minimizing, the ulcer surface reparation.5, itching-relieving action shows: this medicine obviously suppresses the effect of scratching where it itches that histamine produces.6, test shows to scytitis, and the comply with one's wishes golden yellow liniment and the golden yellow emulsifiable paste of complying with one's wishes can resist the mice dermatitis that 2,4 dinitrofluorobenzene produce.Illustrate that the golden yellow liniment of complying with one's wishes has good anti-inflammatory analgetic effect with the golden yellow emulsifiable paste of complying with one's wishes.
1, experiment material
Trial drug the present invention golden yellow emulsifiable paste (hereinafter to be referred as emulsifiable paste as one wishes) of complying with one's wishes, people's consumption 8g every day, every g emulsifiable paste contains crude drug amount 0.5g, is made by the inventive method.
The present invention's golden yellow liniment (hereinafter to be referred as liniment as one wishes) of complying with one's wishes, people's consumption 4g every day crude drug, every ml liniment contains crude drug amount 1g, is made by the inventive method.
Ruyi jinhuang powder, ruyi jinhuang san (loosing hereinafter to be referred as complying with one's wishes) is produced lot number: 010902-1 by Tianjin the 5th pharmaceutical factory of traditional Chinese medicine.
Experimental animal Kunming mouse Wistar rat, Cavia porcellus by Anhui Province medical university animal center provide that it is medium and small, the rat quality certification number, real moving accurate the 01st, No. 03 of Anhui doctor.
2, experimental technique
Analgesic test 2.1 (routine)
2.2 antiinflammatory test
2.2.1 xylol causes the inhibitory action of mice ear
Get 50 of body weight 18-22g male mices, abdominal part takes off row 3 * 3cm
2After be divided into 5 groups (the same) at random.The results are shown in Table 1,2.
2.2.2 Ovum Gallus domesticus album is caused the inhibitory action of rat paw edema
Get 50 of body weight 180-220g male rats, abdominal part depilation 40cm
2After be divided into 5 groups at random, each group is with the same 2.1.1 of concentration, topical administration press the 0.5ml/100g body weight, suitably fixes continuous use 7 days.The results are shown in Table 3-6.
2.2.3 cotton pellet method is caused the inhibitory action of rat granulation hyperplasia
Get 50 of body weight 180-220g male rats, the about 40cm of abdominal part depilation
2After, be divided into 5 groups at random, under the etherization aseptic condition, through autoclaving, each cotton balls adds ampicillin 1mg/0 with the cotton balls of having weighed, 1ml, after 50 ℃ of oven dry, it is subcutaneous to implant rat right side groin.The results are shown in Table 7,8.
2.3 wound is caused the effect of stasis of blood model
Get 60 of body weight 200-250g rats, the right hind depilation, behind the 24h, be divided into 6 groups at random, other rat right hind legs at different levels are separately fixed on the bottom platform of homemade freely falling body device except that normal group, freely fall from the 15cm eminence with 50 gram counterweights, continuous 5 times, cause the hind leg blood stasis and cause the wound rat model, then at the blood stasis position by table 13 dosage topical administration (liniment concentration is respectively 50,25,12.5%) 0.5ml/100g body weight, continuous 4d.The result is as follows.
2.3.1 all there is obvious swelling each Mus part after the perusal modeling, blue, the oozing of blood of local skin, and the treatment back still has the mild swelling except that the model group part, and all the other each groups do not see that obvious pathological changes is arranged.
2.3.2 mirror is observed down and is found the ruyi jinhuang powder, ruyi jinhuang san group and the large, medium and small dosage group of the golden yellow liniment group pathological changes that complies with one's wishes all has than model group and alleviates, and illustrate that golden yellow liniment as one wishes has certain therapeutic effect to skin, flesh wound.
2.4 antibacterial tests
2.4.1 in-vitro antibacterial test
2.4.1.1 strain and culture medium:
Strain: staphylococcus aureus 10 strains (containing type strain ATCC25923), alpha streptococcus 8 strains, group B streptococcus 5 strains, escherichia coli 9 strains (containing reference culture ATCC25922), bacillus pyocyaneus 10 strains, Candida albicans 7 strains, more than 6 kind of 49 strain bacterial strain, wherein reference culture is preserved the center from Beijing biological product check institute strain, and all the other bacterial strains provide by first and second clinical cultivation of attached institute of Anhui Chinese Medicine College.Strain was write " national Clinical Laboratory rule of operation " in 1997 according to Ministry of Public Health Department of Medical Administration and is identified.
Culture medium is selected the MH culture medium for use; Candida albicans is selected husky Bao Shi maintenance base for use; Detest O
2Bacterium is with detesting O
2Culture medium.
2.4.1.2MIC test
The preparation of pastille culture medium: in cultivating, add good as one wishes golden yellow liniment medicinal liquid of prepared beforehand and ruyi jinhuang powder, ruyi jinhuang san contrast medicine respectively, make the drug level of culture medium be respectively 200mg/ml, 100mg/ml, 50mg/ml, 25mg/ml, 12.5mg/ml, 6.25mg/ml, 3.125mg/ml, 1.56mg/ml with two-fold dilution's method for examination.
Confession examination bacterial classification inoculation: once (bacteria containing amount is about 10 to get confession examination bacterium liquid respectively with inoculating loop
4CFU/ml) be inoculated on the culture medium of different pharmaceutical concentration, hatch for 37 ℃ and cultivate 24h, after Candida albicans was cultivated 48h, observed result the results are shown in Table 9,10.
2.4.2 antagonism bacterial skin infections test
2.4.2.1 test method is got 60 of the Kunming mouses that body weight is 18-22g, male and female half and half, every Mus back depilation 3 * 3cm
2, skin is frayed to oozing of blood with sand paper in depilation place, except that staying 10 mices to do the normal group, it does mice is 3 * 10 at the damaged skin subcutaneous injection through the prerun bacterial concentration
8The staphylococcus aureus 0.5ml of CFU/ml, every day 1 time, continuous 3 times, the skin appearance is red and swollen, the purulence thing oozes out, ulcer etc. infected phenomenons after 5 days.With infecting mouse be divided into model group, ruyi jinhuang powder, ruyi jinhuang san group (50%) at random, the golden yellow liniment of complying with one's wishes is little, in, heavy dose of group (12.5%, 25%, 50), successive administration 5 days (being coated with dose 0.1ml/10g body weight) according to dosage, wherein normal group and model group are given isodose excipient.
2.4.2.2 result of the test
1, perusal:
(1) behind the injection golden Portugal bacterium, local skin swelling has ulcer, has purulence, inflammatory thing to ooze out, and normal group skin is without any reaction, and it is normal that the skin of galling recovers.
(2) after the medication, after the 1st medication respectively organized in treatment, inflammatory exudation stops, the purulence thing disappears, ulcer surface dwindles, beginning in the 2nd day, and obviously visible skin begins to repair, rubescent, incrustation, cut off skin and find have the congestion necrosis except that indivedual mices are subcutaneous, the overwhelming majority is subcutaneous not to have obvious difference with normal group; Beginning in the 3rd day, crust comes off, and skin is repaired substantially.And model group ulcer increases the weight of, and purulence, inflammatory thing ooze out and increase, and ulcer surface strengthens, and cuts off skin and finds that mice is subcutaneous to be had outside obvious congestion, the necrosis, with the normal group ratio, significant difference is arranged.
2, mirror is observed down:
Normal control group epidermis and subcutaneous tissue there is no pathological changes; The model group epidermis all has ulcer, and ulcer surface has a large amount of neutrophilic leukocytees and fiber to ooze out, and subcutaneous tissue has lamellar necrosis and microabscess to form, and hyperemia, edema, cell infiltration and hemorrhage are arranged around the pathological changes; The most of ulcer of medication group is not obvious, but inflammatory exudation is arranged, and downright bad abscess only appears at the minority animal in the subcutaneous tissue, and congestion and edema, cell infiltration also have and alleviate.Wherein the sick amount of group is light in a small amount.Positive group pathological changes also has and alleviates.
2.5 antipruritic test
Get 50 of body weight 250-300 Cavia porcelluss, medicine is spread upon left fore cropping zone, every the 0.1ml/100g of local application body weight, concentration is the same, behind the 40min, in the histamine phosphate 0.05ml/100g of forelimb intradermal injection 0.2% body weight, the results are shown in Table 11,12.
Golden yellow liniment is to 2 2.6 comply with one's wishes, the inhibitory action of the dermatitis that the 4-dinitrofluorobenzene produces
Getting body weight is 50 of 25-30g mices, and random packet is the same.Be coated with 0.5% 2,4-dinitrofluorobenzene (DNFB) 25 μ l sensitization, simultaneously with contain crude drug amount 50%, 25%, 12.5% liniment and 50% JINHUANG SAN by 0.1ml/ dosage continuously left ear administration 6 days, be coated with 0.25%DNFB20 μ l at the hard of hearing face in a mice left side in 6 hours and bring out dermatitis behind the 6th day medicine, auris dextra is coated with the solvent of equivalent.The results are shown in Table 13,14.
Table 1, the golden yellow liniment xylol of complying with one's wishes cause inhibitory action (n=10, the x ± s) of mice ear
| Group | Number of animals (n) | Dosage (g/kg) | Swelling degree (mg) | Suppression ratio (%) |
| The excipient group group of loosing as one wishes liniment group (little) as one wishes liniment group as one wishes (in) liniment group (greatly) as one wishes | 10 10 10 10 10 | Equivalent 5.00 1.25 2.50 5.00 | 0.0122±0.0017 0.0084±0.0014 ** 0.0107±0.0013 0.0094±0.0012 ** 0.0087±0.0010 ** | / 15.00 12.00 22.80 28.79 |
With the excipient group than * P＜0.05
Table 2, the golden yellow emulsifiable paste xylol of complying with one's wishes cause inhibitory action (n=10, the x ± s) of mice ear
| Group | Number of animals (n) | Dosage (g/kg) | Swelling degree (mg) | Suppression ratio (%) |
| The excipient group group of loosing as one wishes emulsifiable paste group (little) as one wishes emulsifiable paste group as one wishes (in) emulsifiable paste group (greatly) as one wishes | 10 10 10 10 10 | Equivalent 5.00 1.25 2.50 5.00 | 0.0114±0.0018 0.0090±0.0019 ** 0.0091±0.0021 * 0.0032±0.0011 ** 0.0082±0.0020 ** | / 21.40 20.79 28.73 28.65 |
With the excipient group than * P＜0.05 * * P＜0.01
Table 3, the golden yellow liniment of complying with one's wishes cause inhibitory action (n=10, the x ± s) of rat paw edema to Ovum Gallus domesticus album
| Group | Dosage (g/kg) | Swelling degree (ml) | |||||
| Normal value | 0.5 | 1 | 1.5 | 2 | 3(h) | ||
| The excipient group group of loosing as one wishes liniment group (little) as one wishes liniment group as one wishes (in) liniment group (greatly) as one wishes | Equivalent 2.500 0.625 1.250 2.500 | 1.67±0.16 1.69±0.11 1.64±0.14 1.68±0.19 1.66±0.17 | 1.19±0.25 1.18±0.15 1.12±0.20 0.94±0.28 * 0.65±0.29 ** | 1.45±0.18 1.24±0.16 1.30±0.22 1.20±0.30 * 0.84±0.27 ** | 1.55±0.16 1.15±0.20 ** 1.37±0.24 1.14±0.42 * 1.07±0.41 ** | 1.37±0.13 1.00±0.15 ** 1.13±0.24 ** 1.01±0.35 ** 1.03±0.32 ** | 1.18±0.13 0.80±0.13 ** 0.89±0.24 ** 0.84±0.30 ** 0.77±0.27 ** |
With the excipient group than * P＜0.05 * * P＜0.01
Table 4, the golden yellow emulsifiable paste of complying with one's wishes cause inhibitory action (n=10, the x ± s) of rat paw edema to Ovum Gallus domesticus album
| Group | Dosage (g/kg) | Swelling degree (ml) | |||||
| Normal value | 0.5 | 1 | 1.5 | 2 | 3(h) | ||
| The excipient group group of loosing as one wishes emulsifiable paste group (little) as one wishes emulsifiable paste group as one wishes (in) emulsifiable paste group (greatly) as one wishes | Equivalent 2.500 0.625 1.2501 2.500 | 1.67±0.18 1.62±0.18 1.68±0.18 1.67±0.23 1.64±0.21 | 1.09±0.20 0.98±0.24 1.02±0.34 1.04±0.36 1.05±0.46 | 1.41±0.24 1.34±0.15 1.37±0.32 1.41±0.27 1.31±0.31 | 1.51±0.17 1.38±0.19 1.38±0.24 1.26±0.31 * 1.24±0.24 ** | 1.44±0.26 1.13±0.28 * 1.09±0.26 ** 1.05±0.28 ** 1.04±0.25 ** | 1.44±0.30 0.98±0.31 ** 0.91±0.25 ** 0.81±0.23 ** 0.88±0.23 ** |
With the excipient group than * P＜0.05 * * P＜0.01
Table 5, the golden yellow liniment of complying with one's wishes cause suppression ratio (n=10, the x ± s) of rat paw edema to Ovum Gallus domesticus album
| Group | Dosage (g/kg) | Suppression ratio (%) | ||||
| 0.5 | 1 | 1.5 | 2 | 3(h) | ||
| The excipient group group of loosing as one wishes liniment group (little) as one wishes liniment group as one wishes (in) liniment group (greatly) as one wishes | Equivalent 2.500 0.625 1.250 2.500 | / 0.84 5.88 21.00 45.40 | / 14.48 10.34 17.24 42.10 | / 25.80 11.60 26.45 30.96 | / 27.00 17.50 26.30 24.80 | / 32.20 24.60 28.89 34.70 |
Table 6, the golden yellow emulsifiable paste of complying with one's wishes cause suppression ratio (n=10, the x ± s) of rat paw edema to Ovum Gallus domesticus album
| Group | Dosage (g/kg) | Suppression ratio (%) | ||||
| 0.5 | 1 | 1.5 | 2 | 3(h) | ||
| The excipient group group of loosing as one wishes emulsifiable paste group (little) as one wishes emulsifiable paste group as one wishes (in) emulsifiable paste group (greatly) as one wishes | Equivalent 2.500 0.625 1.250 2.500 | / 11.92 6.42 4.59 3.67 | / 4.96 2.84 0.00 7.09 | / 8.61 8.61 16.56 17.88 | / 21.53 24.31 27.08 27.78 | / 31.94 36.81 43.75 38.89 |
Table 7, the golden yellow liniment of complying with one's wishes cause inhibitory action (n=10, the x ± s) of rat granulation hyperplasia to cotton pellet method
| Group | Dosage (g/kg) | Granulation heavy (g) | |||
| Weight in wet base | Suppression ratio (%) | Dry weight | Suppression ratio (%) | ||
| The excipient group group of loosing as one wishes liniment group (little) as one wishes liniment group as one wishes (in) liniment group (greatly) as one wishes | Equivalent 2.500 0.625 1.250 2.500 | 0.6550±0.0780 0.5588±0.0927 * 0.6048±0.1056 0.5414±0.0943 0.5445±0.1945 ** | / 14.69 7.66 17.34 16.87 | 0.1427±0.0089 0.1070±0.0200 ** 0.1184±0.0140 ** 0.1072±0.0109 ** 0.0846±0.0303 ** | / 25.02 17.03 24.88 40.71 |
Table 8, the golden yellow emulsifiable paste of complying with one's wishes cause inhibitory action (n=10, the x ± s) of rat granulation hyperplasia to cotton pellet method
| Group | Dosage (g/kg) | Granulation heavy (g) | |||
| Weight in wet base | Suppression ratio (%) | Dry weight | Suppression ratio (%) | ||
| The excipient group group of loosing as one wishes emulsifiable paste group (little) as one wishes emulsifiable paste group as one wishes (in) emulsifiable paste group (greatly) as one wishes | Equivalent 2.500 0.625 1.250 2.500 | 0.5924±0.1585 0.4756±0.622 ** 0.5531±0.0530 0.5154±0.6556 0.4748±0.0468 * | / 19.70 6.63 13.00 19.84 | 0.1309±0.0167 0.1006±0.0149 ** 0.1000±0.0129 ** 0.0973±0.0115 ** 0.0980±0.0083 ** | / 23.50 23.61 25.67 25.15 |
Table 9, the golden yellow liniment agent that complies with one's wishes are to 6 kind of 49 strain antibacterial MIC measurement result
| Strain (strain number) | Ruyi jinhuang powder, ruyi jinhuang san (mg/ml) | Golden yellow liniment agent (mg/ml) complies with one's wishes | Blank | Solvent control | ||||
| MIC R | MIC 50 | MIC 90 | MIC R | MIC 50 | MIC 90 | |||
| Staphylococcus aureus (10) alpha streptococcus (8) group B streptococcus (5) escherichia coli (9) bacillus pyocyaneus (10) candida albicans (7) | 6.25-50 25-50 100-100 100-200 100-200 12.5-50 | 25 100 100 200 200 50 | 25 50 100 100 200 50 | 3.12-12.5 12.5-25 50-100 6.25-100 50-100 1.56-6.25 | 12.5 25 100 25 100 3.12 | 6.25 25 50 12.5 100 3.12 | 0 0 0 0 0 0 | 0 0 0 0 0 0 |
Table 10, the golden yellow emulsifiable paste of complying with one's wishes are to 6 kind of 49 strain antibacterial MIC measurement result
| Strain (strain number) | Golden yellow emulsifiable paste (mg/ml) as one wishes | Ruyi jinhuang powder, ruyi jinhuang san (mg/ml) | ||||
| MIC R | MIC 90 | MIC 50 | MIC R | MIC 90 | MIC 50 | |
| Staphylococcus aureus (10) alpha streptococcus (8) group B streptococcus (5) bacillus pyocyaneus (10) escherichia coli (9) candida albicans (6) | 6.25-12.5 25-100 50-100 100-200 50-200 12.5-50 | 12.5 100 100 200 200 50 | 6.25 50 100 100 100 50 | 6.25-50 25-100 100-100 100-200 100-200 12.5-200 | 25 100 100 200 200 200 | 25 50 100 200 200 200 |
Table 11, (inferior) the golden yellow liniment of complying with one's wishes cause the effect of itching (n=10, x ± s) to antihistamine
| Group | Number of animals (n) | Dosage (g/kg) | The number of times (inferior) of scratching where it itches | Suppression ratio (%) |
| The excipient group group of loosing as one wishes liniment group (little) as one wishes liniment group as one wishes (in) liniment group (greatly) as one wishes | 10 10 10 10 10 | Equivalent 0.500 0.125 0.250 0.500 | 22.80±2.90 13.00±3.50 14.60±3.37 10.60±2.50 9.40±2.37 | / 42.98 35.96 53.51 58.77 |
The result shows by table 17: the golden yellow liniment agent that complies with one's wishes causes to itch to histamine phosphate obvious inhibitory action, with excipient group ratio, notable difference is arranged.
Table 12, the golden yellow emulsifiable paste of complying with one's wishes cause the effect of itching (n=10, x ± s) to antihistamine
| Group | Number of animals (n) | Dosage (g/kg) | The number of times (inferior) of scratching where it itches | Suppression ratio (%) |
| The excipient group group of loosing as one wishes emulsifiable paste group (little) as one wishes emulsifiable paste group as one wishes (in) emulsifiable paste group (greatly) as one wishes | 10 10 10 10 10 | Equivalent 0.500 0.125 0.250 0.500 | 22.20±2.35 11.70±3.77 ** 17.50±3.34 11.00±3.40 ** 9.40±3.17 ** | / 42.08 13.37 45.54 53.47 |
With the vehicle group ratio
*P＜0.05
*P＜0.01
Table 13, the golden yellow liniment agent that complies with one's wishes be to 2, and the inhibitory action of the dermatitis that the 4-dinitrofluorobenzene produces (n=10, x ± s)
| Group | Dosage (g/ only) | Ear thickness difference (mm) | Ear weight difference (g) | |
| Left side ear difference | Left and right sides ear difference | |||
| The excipient group group of loosing as one wishes gel group (little) as one wishes gel group as one wishes (in) gel group (greatly) as one wishes | Equivalent 0.0500 0.0125 0.0250 0.0500 | 0.077±0.014 0.065±0.026 0.068±0.027 0.059±0.014 0.060±0.018 | 0.061±0.015 0.055±0.011 0.057±0.012 0.046±0.011 * 0.041±0.0120 ** | 0.0044±0.0010 0.0036±0.0030 * 0.0044±0.0006 0.0033±0.0010 * 0.0031±0.0008 ** |
With the excipient group than * P＜0.05 * * P＜0.01
Table 14, the golden yellow emulsifiable paste of complying with one's wishes be to 2, and the inhibitory action of the dermatitis that the 4-dinitrofluorobenzene produces (n=10, x ± s)
| Group | Dosage (g/ only) | Ear thickness difference (mm) | Ear weight difference (g) | |
| Left side ear difference | Left and right sides ear difference | |||
| The excipient group group of loosing as one wishes emulsifiable paste group (little) as one wishes emulsifiable paste group as one wishes (in) emulsifiable paste group (greatly) as one wishes | Equivalent 0.0500 0.0125 0.0250 0.0500 | 0.067±0.067 0.055±0.024 0.055±0.020 0.053±0.025 0.056±0.029 | 0.066±0.028 0.044±0.018 0.061±0.017 0.052±0.016 0.044±0.012 * | 0.0445±0.0009 0.0026±0.0010 ** 0.0029±0.0012 ** 0.0031±0.0007 ** 0.0023±0.0007 ** |
With the excipient group than * P＜0.05 * * P＜0.01
From result of the test as seen: the comply with one's wishes golden yellow liniment and the golden yellow emulsifiable paste of complying with one's wishes have good repercussive analgesic effect, are in particular in: 1, significant analgesia role is arranged, can improve the pain threshold of mice, that reduces that acetic acid causes turns round the body number of times; 2, have certain antiinflammatory ability, can suppress dimethylbenzene and cause mice ear, the granulation hyperplasia that rat paw edema that Ovum Gallus domesticus album is caused and cotton balls cause rat also has the obvious suppression effect, with the excipient group than there were significant differences.3, the test of repercussive eliminating stagnation shows: the comply with one's wishes golden yellow liniment and the golden yellow emulsifiable paste of complying with one's wishes can resist the blood stasis phenomenon that freely falling body produces.4, external bacteriostasis shows, the comply with one's wishes golden yellow liniment and the golden yellow emulsifiable paste of complying with one's wishes have certain inhibitory action to 6 kinds of antibacterials, and the golden yellow liniment of wherein complying with one's wishes is to the strongest MIC of Candida albicans effect
503.12mg/ml; And the golden yellow emulsifiable paste of complying with one's wishes is to the strongest MIC of candida albicans
506.25mg/ml the local skin infection experiment shows that the comply with one's wishes golden yellow liniment and the golden yellow emulsifiable paste of complying with one's wishes obviously resist the skin infection that staphylococcus aureus causes, and make the very fast disappearance of purulence thing, ooze out minimizing, the ulcer surface reparation.5, itching-relieving action shows: this medicine has obviously antipruritic to scratching of antihistamine generation.6, test shows to scytitis, and the comply with one's wishes golden yellow liniment and the golden yellow emulsifiable paste of complying with one's wishes can resist 2, the dermatitis that the 4-dinitrofluorobenzene produces.Illustrate that the golden yellow liniment of complying with one's wishes has tangible analgesia, antiinflammatory, repercussive and itching relieving effect with the golden yellow emulsifiable paste external that complies with one's wishes.
The specific embodiment
Embodiment 1
Get Rhizoma Curcumae Longae 2.5kg, Radix Angelicae Dahuricae 2.5kg, Rhizoma Atractylodis 1kg, Pericarpium Citri Reticulatae 1kg, Cortex Magnoliae Officinalis 1kg, add 90% ethanol percolation, collect and just filter liquid 8L, carried out determination of volatile oil routinely as A liquid.Continue to collect the continuous liquid 80L that filters, decompression recycling ethanol is concentrated into every 1ml and is equivalent to contain the 5g crude drug; Other gets Radix Et Rhizoma Rhei 2.5kg, Cortex Phellodendri 2.5kg, Radix Trichosanthis 5kg, Radix Glycyrrhizae 1.25kg, Arisaema Cum Bile 1.25kg.Add 10 times of amount 60% alcohol reflux 2 times, each 1.5 hours, filter, merging filtrate reclaims ethanol, is concentrated into every 1ml and is equivalent to contain the 2g crude drug; Merge concentrated solution, as B liquid.Carrying out chrysophanol HPLC routinely measures.
Embodiment 2
Golden yellow liniment as one wishes: get A liquid 4L and add laurocapram 400ml, mixing; Other gets B liquid 4L and adds the about 400ml of polyoxyethylene sorbitan monoleate and propylene glycol 600ml and glycerol 1000ml, mixing; Above-mentioned two liquid are mixed, and adding 65% ethanol to full dose is 10L.Put 0-10 ℃ of cold preservation 24 hours, filter, embedding, check, promptly.
Embodiment 3
Golden yellow liniment as one wishes: get A liquid 4L and B liquid 4L, two liquid mix, and adding 70% ethanol to full dose is 10L.Put 0-10 ℃ of cold preservation 24 hours, filter, embedding, check, promptly.
Embodiment 4
Golden yellow liniment as one wishes: get A liquid 4L and add dimethyl sulfoxide 400ml, mixing; Other gets B liquid 4L and adds about 400ml of polysorbate 40 and PEG 400ml 60% ethanol 1000ml, mixing; Above-mentioned two liquid are mixed, and adding 60% ethanol to full dose is 10L.Put 0-10 ℃ of cold preservation 24 hours, filter, embedding, check, promptly.
Embodiment 5
The golden yellow emulsifiable paste of complying with one's wishes: get A liquid 4L, add PVPK30 1.2kg, stir and make dissolving, as 1.; B liquid is concentrated into every 1ml contains the solution that is equivalent to the 4g crude drug, get 2L, glycerol adding 4kg and lauryl sodium sulfate aqueous solution (400g is dissolved in the 3.2L water) are mixed, and after 30 minutes, move to 75 ℃ of water-baths in the boiling water bath heating, as 2.; With lanoline 1.12kg, stearic acid 1.26kg, hexadecanol 1.12kg, glyceryl monostearate 0.5kg, after heating is dissolved, add laurocapram 0.66L, mixing is put boiling water bath heating 30 minutes, is cooled to 75 ℃, as 3.; During the limit edged stirred and 3. slowly adds 2., insulated and stirred 10 minutes continued to be stirred to temperature and reduces to 42-45 ℃, and the insulation conduct 4.; To 1. be incubated to stir to 35-40 ℃ of back edged and slowly add 4., and weigh, mixed liquor to the total amount of replenishing glycerol-water (1: 1) of 35-40 ℃ is 20kg, insulated and stirred evenly after, constantly be stirred to the nature condensation.The degassing, packing, promptly.
Embodiment 6
A liquid 195ml
B liquid (the 195ml of 4g crude drug/ml)
30 POVIDONE K 30 BP/USP 30 60g
Sodium lauryl sulphate 20g
Glycerol 200g
Lanoline 56g
Stearic acid 63g
Hexadecanol 56g
Glyceryl monostearate 25g
Glycerol-water (1: 1) is an amount of
Make 1000g
Adding adds the laurocapram of weight ratio 3% by gross weight 1000g.Preparation method is with embodiment 5.
In the present embodiment, hexadecanol, glyceryl monostearate, laurocapram, glycerol-water (1: 1) all can omit.30 POVIDONE K 30 BP/USP 30 can substitute with beta-schardinger dextrin-or 30 POVIDONE K 30 BP/USP 15.Glycerol can substitute with PEG400.Lanoline can substitute with vaseline or liquid paraffin.
Embodiment 7
Golden yellow gel as one wishes: get carbomer 0.28kg, add water 7L, stirring and dissolving leaves standstill and got 4% carbomer gel in 24 hours; Get B liquid 4L, add propylene glycol 1.6kg, stirring and evenly mixing, the limit edged stirs and is added in the carbomer hydrogel, stirs, and under agitation adds triethanolamine and transfers PH5～8, stirs, and is standby; Get A liquid 4L, add the 0.6kg laurocapram, mixing, the limit edged stirs and is added in the above-mentioned initial gel, stirs, and adds water to 20kg, abundant mixing, packing, promptly.
Embodiment 8
A liquid 195ml
B liquid 195ml
Carbomer 14g
Propylene glycol 80g
Laurocapram 30g
Triethanolamine is an amount of
Water is an amount of
Make 1000g
Method is with embodiment 7.
Claims (10)
1, a kind of externally-applied medicinal composition, available following method preparation:
Get 2～3 parts in Rhizoma Curcumae Longae, 2～3 parts of the Radixs Angelicae Dahuricae, 0.5～2 part of Pericarpium Citri Reticulatae, 0.5～2 part of Cortex Magnoliae Officinalis, 0.5～2 part of Rhizoma Atractylodis by weight, with 85～95% ethanol percolations, the concentrating under reduced pressure percolate gets concentrated solution A to 5g crude drug/ml;
Get 2～3 parts of Radix Et Rhizoma Rhei, 2～3 parts of Cortex Phellodendris, 1 part in Radix Glycyrrhizae, 1 part of Arisaema Cum Bile, 4～6 parts of Radix Trichosanthis by weight, with 55～65% alcohol reflux; Concentrate ethanol liquid to 2g or 4g crude drug/ml, get concentrated solution B;
Get 1 part of A concentrated solution by volume: B concentrated solution 0.5-1 part, mix with pharmaceutically acceptable carrier.
2, according to the described pharmaceutical composition of claim 1, it is characterized in that:
Get 2.5 parts in Rhizoma Curcumae Longae, 2.5 parts of the Radixs Angelicae Dahuricae, 1 part of Pericarpium Citri Reticulatae, 1 part of Cortex Magnoliae Officinalis, 1 part of Rhizoma Atractylodis by weight, use 90% ethanol percolation, the concentrating under reduced pressure percolate gets concentrated solution A to 5g crude drug/ml;
Get 2.5 parts of Radix Et Rhizoma Rhei, 2.5 parts of Cortex Phellodendris, 1 part in Radix Glycyrrhizae, 1 part of Arisaema Cum Bile, 5 parts of Radix Trichosanthis by weight, with 8～10 times of amount 60% alcohol reflux; Concentrate ethanol liquid to 2g or 4g crude drug/ml, get concentrated solution B.
3, according to claim 1 or 2 described pharmaceutical compositions, it is characterized in that: make liniment, ointment, tincture, unguentum, rubber-emplastrum, emplastrum, gel or cataplasma.
4, according to the described pharmaceutical composition of claim 3, it is characterized in that: liniment mainly is made up of with an amount of 50-75% ethanol 1 part of the B concentrated solution of 1 part of the A concentrated solution of 5g crude drug/ml by volume, 2g crude drug/ml.
5, according to the described pharmaceutical composition of claim 4, it is characterized in that: also comprise 3～4.5% laurocaprams and/or dimethyl sulfoxide, 3～4.5% Tween-80s, polysorbate 60 and/or polysorbate 40,5～7% propylene glycol and/or PEG400 by volume in the liniment, and an amount of glycerol.
6, the described preparation of drug combination method of claim 5 is characterized in that comprising the steps:
Get 1 part of A concentrated solution and 3～4.5% laurocaprams and/or dimethyl sulfoxide mixing; Get 1 part of B concentrated solution and 3～4.5% polyoxyethylene sorbitan monoleate, polysorbate 60 and/or polysorbate 40,5～7% propylene glycol and/or PEG400 and an amount of glycerol mixing; Above-mentioned two liquid are mixed, add an amount of ethanol.
7, according to the described pharmaceutical composition of claim 3, it is characterized in that: ointment is mainly by 50 parts of the B concentrated solutions of 100 parts of the A concentrated solutions of by volume 5g crude drug/ml, 4g crude drug/ml, with 30 POVIDONE K 30 BP/USP 30, beta-schardinger dextrin-and/or 15 25～35 parts of 30 POVIDONE K 30 BP/USPs, 15～25 parts of sodium lauryl sulphates, glycerol and/or 190～240 parts of PEG400, lanoline, vaseline and/or 22～30 parts of liquid paraffin, 25～35 parts of compositions of stearic acid by weight.
8, according to the described pharmaceutical composition of claim 7, it is characterized in that: comprise also in the ointment that 18～38 parts of hexadecanol, 6～18 parts, 1: 1 glycerol of glyceryl monostearate and aqueous mixtures are an amount of by weight, and the laurocapram of gross weight 2～4%.
9, described according to Claim 8 pharmaceutical composition, it is characterized in that: ointment is basically by 50 parts of the B concentrated solutions of 100 parts of the A concentrated solutions of 5g crude drug/ml, 4g crude drug/ml, with 3025～35 parts of 30 POVIDONE K 30 BP/USPs, 15～25 parts of sodium lauryl sulphates, 190～240 parts of glycerol, 22～30 parts of lanolines, 25～35 parts of stearic acid, 20～30 parts of hexadecanol, 8～14 parts, 1: 1 glycerol of glyceryl monostearate and aqueous mixtures are an amount of by weight, and the laurocapram of gross weight 2.5～3.5% is formed.
10, the described preparation of drug combination method of claim 9 is characterized in that comprising the steps:
The A concentrated solution of getting 5g crude drug/ml by volume 100 parts mix for 3025～35 parts with 30 POVIDONE K 30 BP/USP by weight and to make dissolving, 1;
The B concentrated solution of getting 4g crude drug/ml by volume 50 parts mix for 190～240 parts with 15～25 parts of sodium lauryl sulphates and glycerol by weight, heating in water bath, 2;
Get 20～30 parts of 22～30 parts of lanolines, 25～35 parts of stearic acid, hexadecanol by weight and mix for 8～14 parts with glyceryl monostearate, after the heat fused, add the laurocapram by gross weight 2.5～3.5%, mixing heats in the water-bath, 3;
Mix with 23, insulation 75 degree are cooled to 42～45 degree, as 4;
1 insulation to 35～40 degree, is added in 4, and 1: 1 the glycerol and the aqueous mixtures that replenish 35～40 degree are an amount of, natural condensation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB031132901A CN1308030C (en) | 2003-04-25 | 2003-04-25 | Medicine combination containing valid part of Ruyi Jinhuangsan and its preparing method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB031132901A CN1308030C (en) | 2003-04-25 | 2003-04-25 | Medicine combination containing valid part of Ruyi Jinhuangsan and its preparing method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1444977A CN1444977A (en) | 2003-10-01 |
| CN1308030C true CN1308030C (en) | 2007-04-04 |
Family
ID=27814688
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB031132901A Expired - Fee Related CN1308030C (en) | 2003-04-25 | 2003-04-25 | Medicine combination containing valid part of Ruyi Jinhuangsan and its preparing method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1308030C (en) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100340230C (en) * | 2004-07-23 | 2007-10-03 | 童玉新 | 'Ruyi Jinhuang' gel and method for preparing the same |
| CN100333720C (en) * | 2005-01-11 | 2007-08-29 | 中国人民解放军第二军医大学 | Compound analgesic agent |
| CN101288760B (en) * | 2008-06-18 | 2012-07-25 | 张松柏 | Externally-used drug for treating appendicitis |
| CN103393918B (en) * | 2013-07-25 | 2015-01-28 | 山西省中医药研究院 | Compounded garcinia and radix angelicae ointment for preventing and treating chemotherapeutic phlebitis |
| CN106833973A (en) * | 2017-01-18 | 2017-06-13 | 广西南宁博智生物科技有限公司 | A kind of cold process soap for acne of dispelling and preparation method thereof |
| CN110680892A (en) * | 2018-07-04 | 2020-01-14 | 黑龙江燎原科技有限公司 | Cataplasm hot patch for relieving pain of tumor |
| CN109453343A (en) * | 2018-12-26 | 2019-03-12 | 贾力力 | A kind of Traditional Chinese medicinal poultice for treating skin sore rash |
| CN110694011A (en) * | 2019-11-07 | 2020-01-17 | 刘兰香 | External application medicine for infantile phlebotomy injury phlebitis |
| CN114569691A (en) * | 2020-06-30 | 2022-06-03 | 南昌市第九医院 | Traditional Chinese medicine composition for repairing vein treatment part and preparation method and application of pasty preparation of traditional Chinese medicine composition |
| CN112121134A (en) * | 2020-08-26 | 2020-12-25 | 王利娟 | Traditional Chinese medicine composition for treating joint cavity effusion and preparation method thereof |
| CN115154571A (en) * | 2022-08-18 | 2022-10-11 | 西南民族大学 | A kind of antibacterial composition and its application |
| CN116509826B (en) * | 2023-02-13 | 2024-12-03 | 湖北省农业科学院畜牧兽医研究所 | Application of magnolol or composition of magnolol and EGCG in inhibiting mycoplasma gallisepticum and mycoplasma synoviae |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1163762A (en) * | 1996-04-26 | 1997-11-05 | 韩殿卫 | Chinese patent medicine for treating tracheitis and emphysema |
| CN1191746A (en) * | 1998-03-05 | 1998-09-02 | 韩殿卫 | Chinese medicine for treating inflammation |
| CN1365781A (en) * | 2001-01-19 | 2002-08-28 | 杨孟君 | Nano medicine 'Ruyi Jinhuang' and its preparing process |
-
2003
- 2003-04-25 CN CNB031132901A patent/CN1308030C/en not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1163762A (en) * | 1996-04-26 | 1997-11-05 | 韩殿卫 | Chinese patent medicine for treating tracheitis and emphysema |
| CN1191746A (en) * | 1998-03-05 | 1998-09-02 | 韩殿卫 | Chinese medicine for treating inflammation |
| CN1365781A (en) * | 2001-01-19 | 2002-08-28 | 杨孟君 | Nano medicine 'Ruyi Jinhuang' and its preparing process |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1444977A (en) | 2003-10-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1308030C (en) | Medicine combination containing valid part of Ruyi Jinhuangsan and its preparing method | |
| CN108888676B (en) | A kind of traditional Chinese medicine composition for treating eczema and preparation method thereof | |
| CN101062289A (en) | External application medicine combination for treating gout | |
| CN101732669A (en) | Traditional Chinese medicine used for treating gynecologic inflammation, preparation method and application thereof | |
| CN100340230C (en) | 'Ruyi Jinhuang' gel and method for preparing the same | |
| CN1679888A (en) | Decoction Chinese medicine sterilizing antiphlogistic, preparation and use thereof | |
| CN103417937B (en) | Clean spray of Corallium Japonicum Kishinouye tinea and preparation method thereof | |
| CN101716209A (en) | Artemisia dalai-lamae Krasch. essential oil and preparation method and application thereof | |
| CN104127743A (en) | Application of traditional Chinese medicinal lotion in preparation of tinea pedis treatment medicines | |
| CN101053612A (en) | External applied traditional Chinese medicine vagina cleaning agent for curing gynecopathy and vagina cleaning ointment thereof | |
| CN1219527C (en) | Ointment for curing acne and its preparation method | |
| CN110279754B (en) | Traditional Chinese medicine granule for treating suppurative dermatosis, preparation method and application thereof | |
| CN1285360C (en) | Medicine compound having synergistic action | |
| CN103316103B (en) | Coccidian-expelling and dysentery-stopping mixture for livestock and preparation method thereof | |
| CN1251702C (en) | Externally applied medicine for treating women's inflammation and its prepn process | |
| CN101234140A (en) | A kind of pharmaceutical composition for treating eczema and its preparation method and application | |
| CN105687730B (en) | A kind of compound recipe Rhizoma Corydalis Chinese medicine composition for local analgesia | |
| CN104147434A (en) | Chinese herbal lotion for treating tinea pedis | |
| CN104547325A (en) | Medicinal composition for treating chronic idiopathic urticaria and application thereof | |
| CN1827150A (en) | External-use emulsion membrane for treating rheumatism and preparation method thereof | |
| CN1726955A (en) | Compound soft capsule of earthworm and preparation method | |
| CN101837079B (en) | Anti-inflammatory analgesic or anti-inflammatory immune medicinal composition, preparation method and application thereof | |
| CN1843418A (en) | Chinese medicine extract for treating gastroenteritis and Chinese medicine composition containing the extract | |
| CN116585397A (en) | A pharmaceutical composition for treating eczema-like skin diseases, its preparation method and application | |
| CN105055622A (en) | Traditional Chinese medicine film-forming gel for treating shallow bed-sore at ulceration |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| PP01 | Preservation of patent right |
Effective date of registration: 20131021 Granted publication date: 20070404 |
|
| RINS | Preservation of patent right or utility model and its discharge | ||
| PD01 | Discharge of preservation of patent |
Date of cancellation: 20140421 Granted publication date: 20070404 |
|
| RINS | Preservation of patent right or utility model and its discharge | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20070404 Termination date: 20140425 |